Seeking Alpha

Sarepta Therapeutics (SRPT +6.5%) moves up after the FDA granted Fast Track approval status for...

Sarepta Therapeutics (SRPT +6.5%) moves up after the FDA granted Fast Track approval status for it's lead drug candidates, AVI-7288 and AVI-7537, for Ebola and Marburg viruses respectively. Both drugs are being developed under a U.S. Department of Defense contract. AVI-7288 will start an upcoming Phase I multiple ascending dose study, however, development of AVI-7537 remains under a temporary stop-work order due to funding constraints.
Comments (1)
  • largrasr
    , contributor
    Comments (2) | Send Message
     
    Makes their product offering more than a one pony show; should attract serious buy-out interest
    18 Sep 2012, 05:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|